Biocon Pharma Limited - Due diligence report

A 360° intelligence report on Biocon: trust score, financial health, credit view, compliance, directors, growth and distress signals - gener…

2014-10-31 Bangalore, Karnataka Active Unlisted Active Compliant
Share
View plans
BP Biocon Pharma Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Biocon — 360° Intelligence Report

Generated from MCA filings & public records
71/100
Trust Score
Moderate

Biocon is assessed as Moderate with a Trust Score of 71/100. Biocon is an active public limited indian non-government company incorporated in 2014, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 28 Jun 2026 from the latest processed filings. Biocon Pharma Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
71/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
35/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
45/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 1 satisfied (133.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Citi Bank N.A.1 48.0 cr
Compliance Score: 86/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 2 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
KIRAN MAZUMDAR SHAW 01234567 Director 01/04/2018 6 yrs Approved
SIDDHARTH MITTAL 01234567 Director 01/04/2018 6 yrs Approved
SOUDABI NEDUVANCHERY 01234567 Director 01/04/2018 6 yrs Approved
KARAIKAL NARAYANASWAMY MURALI KRISHNAN 01234567 Director 01/04/2018 6 yrs Approved
Mayank Verma 01234567 Director 01/04/2018 6 yrs Approved
Soudabi Neduvanchery 01234567 Director 01/04/2018 6 yrs Approved
  • 6 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Biocon Limited
Subsidiaries
-
Group entities
-
Capital events
11 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Biocon Pharma Inc. Subsidiary Company 74.00%
Biocon Pharma Ireland Limited Subsidiary Company 74.00%
Biocon Pharma Malta I Limited Subsidiary Company 74.00%
Biocon Pharma Malta Limited Subsidiary Company 74.00%
Biocon Pharma Uk Limited Subsidiary Company 74.00%
Biocon Limited Holding Company 74.00%

Key managerial personnel: SIDDHARTH MITTAL (Whole-time director) · SOUDABI NEDUVANCHERY (CFO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 80 · Distress 45
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 11+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Outside liabilities up 24% in a year.
Negative net worth.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence69/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment57/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view62/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
08 Aug 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
29 Aug 2024
Director appointed
Soudabi Neduvanchery (Cfo)
08 Aug 2024
Director appointed
SOUDABI NEDUVANCHERY (CFO)
31 Jul 2022
Director ceased
JOHN MCCALLUM MARSHALL SHAW
22 Jul 2022
Director ceased
KARAIKAL NARAYANASWAMY MURALI KRISHNAN
31 May 2022
Charge satisfied
Citi Bank N.A.
13 May 2022
Director appointed
KARAIKAL NARAYANASWAMY MURALI KRISHNAN (Director)
28 Apr 2021
Director ceased
ANUPAM JINDAL
26 Mar 2021
Securities allotted
53000000 Preference Shares - 53.00 cr raised
15 Mar 2021
Securities allotted
218011288 Preference Shares - 218.01 cr raised
21 Jan 2021
Securities allotted
77470378 Preference Shares - 77.47 cr raised
22 Oct 2020
Securities allotted
248459371 Preference Shares - 248.46 cr raised
Director appointed
Mayank Verma (Company Secretary)
Director ceased
INDRANIL SEN
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Compliance record is strong - status, filings and flags are clean.
6 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Capital has been raised through 11 security allotment(s) - amounts available in the full report.
20 overseas direct investment(s) (ODI) on record - international footprint.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
New India Detergents Private Limited U24240DL1989PTC036220 New Delhi, Delhi, India
Empee Distilleries U15511TN1983PLC010313 Chennai, Tamil Nadu, India
Monarchcatalyst U24110MH1983PTC031365 Thane, Maharashtra, India
Sandhya Group U24110GJ1992PTC017399 Vapi, Gujarat, India
Kiri Industries L24231GJ1998PLC034094 Ahmedabad, Gujarat, India
Akin Chemicals Private Limited U51496MH1997PTC109677 Mumbai, Maharashtra, India
Apotex U73100KA2003PTC032103 Jigani Hobli, Karnataka, India
Takeda U24231MH1999PTC119171 Navi Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Biocon before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Biocon: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 80/100, margin trends, ownership structure and peer set for Biocon - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 71/100, distress signals and MSME payment-delay disclosures - know whether Biocon pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Biocon - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Biocon an active company?

Biocon has MCA status “Active” with a compliance score of 86/100 (Low Risk).

Is Biocon financially healthy?

Biocon has a Financial Health Score of 35/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Biocon?

Its overall Trust Score is 71/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Biocon?

The ultimate holding entity is Biocon Limited. 6 active director(s) are on record.

Does Biocon have loans or charges against its assets?

No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Biocon up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).

Is it risky to lend to Biocon?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.